A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Inclusion Criteria:

Locally advanced or metastatic HER2-expressing (IHC 2+ or 3+) or amplified solid tumor
Subjects must have received prior therapies known to confer clinical benefit (unless ineligible or refused to receive)
Measurable disease per RECIST 1.1
Tumor lesion amenable for biopsy or able to provide tissue from biopsy within last 6 months
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Adequate hematologic, hepatic, and cardiac function

Exclusion Criteria:

History of allergic reactions to certain components of SBT6050 or similar drugs
Untreated brain metastases
Active autoimmune disease or a documented history of autoimmune disease or syndrome
Human immunodeficiency virus infection, active hepatitis B infection or hepatitis C infection
Additional protocol defined inclusion/exclusion criteria may apply.